Company Profiles

driven by the PitchBook Platform

Oxagen

Description

Developer of small molecule drugs designed to treat inflammatory and respiratory diseases. The company's small molecule drugs comprise of an oral anti-inflammatory agent, CRTH2 antagonist, an oral molecule for asthma and CCRL2, an orphan C-C-chemokine receptor for the treatment of rheumatoid arthritis, atherosclerosis, respiratory diseases, inflammatory bowel disease and allergic dermatitis, enabling patients to receive enhanced results from the medicines.

1996

Founded

PRIVATE

Status

51-200

Employees

2ndary - Private

Latest Deal Type

$169M

Total Amount Raised

13

Investors

Description

Developer of small molecule drugs designed to treat inflammatory and respiratory diseases. The company's small molecule drugs comprise of an oral anti-inflammatory agent, CRTH2 antagonist, an oral molecule for asthma and CCRL2, an orphan C-C-chemokine receptor for the treatment of rheumatoid arthritis, atherosclerosis, respiratory diseases, inflammatory bowel disease and allergic dermatitis, enabling patients to receive enhanced results from the medicines.

Website:

www.oxagen.co.uk

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Delivery

Other Industries

Pharmaceuticals

Primary Office

Innovation Centre 99 Park Drive Milton Park, Oxon Abingdon OX14 4RYEngland +44 (0)12 3584 1561
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Oxagen's full profile, request a free trial.

    Oxagen Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Oxagen Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Oxagen Investors (13)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    3i GroupPE/BuyoutMinority000 0000000 0000
    Aberdeen SVG Private EquityPE/BuyoutMinority000 0000000 0000
    Advent Venture PartnersVenture CapitalMinority000 0000000 0000
    Bessemer Venture PartnersVenture CapitalMinority000 0000000 0000
    International Biotechnology TrustOtherMinority000 0000000 0000
    3i Group PE/Buyout
    Aberdeen SVG Private Equity PE/Buyout
    Advent Venture Partners Venture Capital
    Bessemer Venture Partners Venture Capital
    International Biotechnology Trust Other

    Oxagen Executive Team (1)

    NameTitleBoard
    Seat
    Contact
    Info
    John Bell Ph.DCo-Founder & Board Member
    John Bell Ph.D Co-Founder & Board Member

    Oxagen Board Members (7)

    NameRepresentingRoleSinceContact
    Info
    Alan Ezekowitz Ph.DSelfBoard Member000 0000
    Anja König Ph.DNovartis Venture FundCo-Managing Director000 0000
    Erich SchlickWellington PartnersGeneral Partner000 0000
    John Bell Ph.DSelfCo-Founder & Board Member000 0000
    Luke Evnin Ph.DMPM CapitalCo-Founder & Managing Director000 0000
    Alan Ezekowitz Ph.D Board Member Self
    Anja König Ph.D Co-Managing Director Novartis Venture Fund
    Erich Schlick General Partner Wellington Partners
    John Bell Ph.D Co-Founder & Board Member Self
    Luke Evnin Ph.D Co-Founder & Managing Director MPM Capital
    Request full access to PitchBook